Current and Emerging Therapies in Pancreatic Cancer
作者： Maria Diab , Philip A. Philip
DOI: 10.1007/978-3-319-58256-6_6
关键词: KRAS 、 Disease 、 Biomarker (medicine) 、 Treatment plan 、 Pancreatic cancer 、 Oncology 、 Circulating tumor cell 、 Medicine 、 CA19-9 、 microRNA 、 Internal medicine
摘要: Pancreatic cancer (PC) continues to be the fourth leading cause of cancer-related mortality despite decades attempts eradicate this disease. To day, an effective tool for screening and early diagnosis pancreatic is missing. A number biomarkers was evaluated in diagnostic, therapeutic, prognostic settings cancer. KRAS, which mutated >90% cases, considered a rational target treating Unfortunately, therapy targeting KRAS still lacking. MicroRNAs represent attractive biomarker due their abundance feasibility analysis. Multiple panels microRNAs can differentiate from healthy nonmalignant tissues. Biomarkers, such as hENT1 SPARC, may assist predicting benefit specific therapeutic agents provide patients with “individualized” treatment plan. Furthermore, “liquid biopsies” allow monitoring circulating tumor DNA cells during therapy. However, date, CA 19-9 remains only FDA-approved use clinic.
springer.com
sci-hub.st 参考文章(128)
Steinberg W, The clinical utility of the CA 19-9 tumor-associated antigen The American Journal of Gastroenterology. ,vol. 85, pp. 350- 355 ,(1990)
Mark Sausen, Jillian Phallen, Vilmos Adleff, Siân Jones, Rebecca J Leary, Michael T Barrett, Valsamo Anagnostou, Sonya Parpart-Li, Derek Murphy, Qing Kay Li, Carolyn A Hruban, Rob Scharpf, James R White, Peter J O’Dwyer, Peter J Allen, James R Eshleman, Craig B Thompson, David S Klimstra, David C Linehan, Anirban Maitra, Ralph H Hruban, Luis A Diaz Jr, Daniel D Von Hoff, Julia S Johansen, Jeffrey A Drebin, Victor E Velculescu, None, Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients Nature Communications. ,vol. 6, pp. 7686- 7686 ,(2015) , 10.1038/NCOMMS8686
Brian A. Boone, Shirin Sabbaghian, Mazen Zenati, J. Wallis Marsh, A. James Moser, Amer H. Zureikat, Aatur D. Singhi, Herbert J. Zeh, Alyssa M. Krasinskas, Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer. Journal of Surgical Oncology. ,vol. 110, pp. 171- 175 ,(2014) , 10.1002/JSO.23606
R. H. Hruban, M. Shekher, M. Goggins, W. Hilgers, C. J. Yeo, C. A. Griffin, S. E. Kern, D. Tang, T. A. Sohn, G. J. A. Offerhaus, Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. American Journal of Pathology. ,vol. 152, pp. 1501- 1507 ,(1998)
Talia Golan, Elina Zorde Khvalevsky, Ayala Hubert, Rachel Malka Gabai, Naama Hen, Amiel Segal, Abraham Domb, Gil Harari, Eliel Ben David, Stephen Raskin, Yuri Goldes, Eran Goldin, Rami Eliakim, Maor Lahav, Yael Kopleman, Alain Dancour, Amotz Shemi, Eithan Galun, RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients Oncotarget. ,vol. 6, pp. 24560- 24570 ,(2015) , 10.18632/ONCOTARGET.4183
Ralph H. Hruban, Mieke Schutte, Charles J. Yeo, Henry T. Lynch, Scott E. Kern, Craig L. Weinstein, Charles E. Jackson, Michael Goggins, Gloria M. Petersen, Jia Lu, Christopher A. Moskaluk, Germline BRCA2 Gene Mutations in Patients with Apparently Sporadic Pancreatic Carcinomas Cancer Research. ,vol. 56, pp. 5360- 5364 ,(1996)
Umashankar K Ballehaninna, Ronald S Chamberlain, The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal Journal of gastrointestinal oncology. ,vol. 3, pp. 105- 119 ,(2012) , 10.3978/J.ISSN.2078-6891.2011.021
Hideaki Kinugasa, Kazuhiro Nouso, Koji Miyahara, Yuki Morimoto, Chihiro Dohi, Koichiro Tsutsumi, Hironari Kato, Takehiro Matsubara, Hiroyuki Okada, Kazuhide Yamamoto, Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer. ,vol. 121, pp. 2271- 2280 ,(2015) , 10.1002/CNCR.29364
Manuel Hidalgo, Carlos Plaza, Monica Musteanu, Peter Illei, Carrie B Brachmann, Carla Heise, Daniel Pierce, Pedro P Lopez-Casas, Camino Menendez, Josep Tabernero, Alfredo Romano, Xinyu Wei, Fernando Lopez-Rios, Daniel D Von Hoff, None, SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel Plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Clinical Cancer Research. ,vol. 21, pp. 4811- 4818 ,(2015) , 10.1158/1078-0432.CCR-14-3222
Takahiro Kishi, Akira Nakamura, Satoshi Itasaka, Keiko Shibuya, Shigemi Matsumoto, Masashi Kanai, Yuzo Kodama, Kyoichi Takaori, Takashi Mizowaki, Masahiro Hiraoka, Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer Pancreatology. ,vol. 15, pp. 694- 700 ,(2015) , 10.1016/J.PAN.2015.09.016